Wockhardt FY26 PBT Rs 238 Cr vs Loss YoY

Wockhardt reported FY26 PBT of Rs 238 Cr versus Rs (-)16 Cr loss last year, with 11% revenue growth to Rs 3,373 Cr.
Q4 FY26 revenue grew 30% YoY to Rs 965 Cr with EBITDA surging 147% to Rs 196 Cr and PBT of Rs 189 Cr.
Biotech operations grew 126% in Q4 to Rs 252 Cr, driven by emerging markets and strategic partnerships.
Five novel antibiotics completed Phase 3 trials, with Zaynich receiving EMA accelerated assessment and Miqnaf launched in India.